Spruce Biosciences (SPRB) News Today → “Dollar Will Be Worth NOTHING” -Musk (From Crypto 101 Media) (Ad) Free SPRB Stock Alerts $0.77 -0.03 (-3.75%) (As of 05/16/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 16 at 10:53 AM | markets.businessinsider.comHold Rating on Spruce Biosciences Amid Clinical Trial Uncertainties and Rising CompetitionMay 16 at 6:56 AM | americanbankingnews.comQ2 2024 EPS Estimates for Spruce Biosciences, Inc. (NASDAQ:SPRB) Reduced by AnalystMay 16 at 5:04 AM | americanbankingnews.comSpruce Biosciences (NASDAQ:SPRB) Stock Rating Reaffirmed by HC WainwrightMay 16 at 3:28 AM | americanbankingnews.comHC Wainwright Comments on Spruce Biosciences, Inc.'s FY2025 Earnings (NASDAQ:SPRB)May 16 at 12:14 AM | finance.yahoo.comSpruce Biosciences, Inc. (SPRB)May 15 at 3:26 AM | americanbankingnews.comSpruce Biosciences, Inc. (NASDAQ:SPRB) Receives Consensus Rating of "Hold" from BrokeragesMay 15 at 3:10 AM | markets.businessinsider.comBuy Rating Affirmed for Spruce Biosciences Amid Upcoming Trial Data and Strong Financial PositionMay 13, 2024 | msn.comSPRB Stock Earnings: Spruce Biosciences Beats EPS, Beats Revenue for Q1 2024May 13, 2024 | businesswire.comSpruce Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate UpdatesApril 30, 2024 | finance.yahoo.comSpruce Biosciences Announces Additional Poster Presentation at the Pediatric Endocrine Society 2024 Annual MeetingApril 26, 2024 | investing.comSpruce Biosciences Inc (SPRB)April 22, 2024 | businesswire.comSpruce Biosciences Announces Upcoming Poster Presentation at the Pediatric Endocrine Society 2024 Annual MeetingApril 4, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Spruce Biosciences, Inc. - SPRBMarch 27, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Spruce Biosciences, Inc. - SPRBMarch 23, 2024 | finance.yahoo.comRevenue Downgrade: Here's What Analysts Forecast For Spruce Biosciences, Inc. (NASDAQ:SPRB)March 22, 2024 | insidertrades.comHoldings A/S Novo Sells 359,979 Shares of Spruce Biosciences, Inc. (NASDAQ:SPRB) StockMarch 19, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Spruce Biosciences, Inc. - SPRBMarch 19, 2024 | insidertrades.comSpruce Biosciences, Inc. (NASDAQ:SPRB) Major Shareholder Holdings A/S Novo Sells 1,912,316 SharesMarch 16, 2024 | finance.yahoo.comSpruce Biosciences, Inc. (NASDAQ:SPRB) Just Reported Earnings, And Analysts Cut Their Target PriceMarch 15, 2024 | marketbeat.comSpruce Biosciences (NASDAQ:SPRB) Stock Rating Lowered by Leerink PartnrsLeerink Partnrs lowered shares of Spruce Biosciences from an "outperform" rating to a "market perform" rating in a report on Thursday.March 14, 2024 | marketwatch.comSpruce Biosciences Shares Dive 74% After Terminating Genetic Disease Study, Cutting StaffMarch 14, 2024 | markets.businessinsider.comSpruce Biosciences' Hormone Treatment Stumbles In Trials, Prompts Stock FreefallMarch 14, 2024 | businesswire.comSpruce Biosciences, Inc. (SPRB) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged WrongdoingsMarch 14, 2024 | marketwatch.comStocks to Watch: Spruce Biosciences, UiPathMarch 14, 2024 | markets.businessinsider.comSpruce Biosciences FY23 Loss Widens, CAHmelia-203 Study Fails; Stock Down In Pre-marketMarch 14, 2024 | msn.comWhy Is Rare Endocrine Disorder-Focused Spruce Biosciences Stock Plummeting On Thursday?March 14, 2024 | marketbeat.comSpruce Biosciences (NASDAQ:SPRB) Downgraded by GuggenheimGuggenheim cut Spruce Biosciences from a "buy" rating to a "neutral" rating in a research report on Thursday.March 14, 2024 | investorplace.comWhy Is Spruce Biosciences (SPRB) Stock Down 78% Today?March 14, 2024 | markets.businessinsider.comBuy Rating Affirmed for Spruce Biosciences Amid Clinical Trial Optimism and Advancing Dose CohortsMarch 13, 2024 | msn.comSpruce Biosciences stock craters 75% on failed Phase 2 studyMarch 13, 2024 | finance.yahoo.comSpruce Biosciences Inc (SPRB) Reports Full Year 2023 Financial Results Amid Clinical Trial SetbacksMarch 13, 2024 | marketbeat.comTrading was temporarily halted for "SPRB" at 04:03 PM with a stated reason of "News pending."March 13, 2024 | businesswire.comSpruce Biosciences Reports Full Year 2023 Financial Results and Provides Corporate UpdatesMarch 13, 2024 | businesswire.comSpruce Biosciences Announces Topline Results from CAHmelia-203 in Adult Classic CAH and CAHptain-205 in Pediatric Classic CAHMarch 13, 2024 | marketbeat.comSpruce Biosciences (SPRB) to Release Earnings on ThursdaySpruce Biosciences (NASDAQ:SPRB) will be releasing earnings on Thursday, March 14, Yahoo Finance reports.March 5, 2024 | marketbeat.comSpruce Biosciences' (SPRB) Outperform Rating Reiterated at Royal Bank of CanadaRoyal Bank of Canada reaffirmed an "outperform" rating and issued a $9.00 target price on shares of Spruce Biosciences in a research report on Tuesday.March 3, 2024 | marketbeat.comArmistice Capital LLC Cuts Stake in Spruce Biosciences, Inc. (NASDAQ:SPRB)Armistice Capital LLC trimmed its position in Spruce Biosciences, Inc. (NASDAQ:SPRB - Free Report) by 12.6% in the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 3,056,000 shares of the company's stock after selling 442,000 shares during the pFebruary 26, 2024 | marketbeat.comSpruce Biosciences (NASDAQ:SPRB) PT Raised to $9.00 at Royal Bank of CanadaRoyal Bank of Canada boosted their target price on Spruce Biosciences from $8.00 to $9.00 and gave the company an "outperform" rating in a research report on Monday.February 23, 2024 | benzinga.comSpruce Biosciences Stock (NASDAQ:SPRB), Short Interest ReportFebruary 21, 2024 | msn.comGuggenheim starts Spruce Biosciences at buy, cites near-term catalystsFebruary 21, 2024 | msn.comGuggenheim Initiates Coverage of Spruce Biosciences (SPRB) with Buy RecommendationFebruary 16, 2024 | marketbeat.comAIGH Capital Management LLC Has $2.74 Million Holdings in Spruce Biosciences, Inc. (NASDAQ:SPRB)AIGH Capital Management LLC grew its stake in shares of Spruce Biosciences, Inc. (NASDAQ:SPRB - Free Report) by 9.0% during the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned 1,211,000 shares of the company's stock after buying an additional 100,0February 5, 2024 | marketbeat.comSpruce Biosciences, Inc. (NASDAQ:SPRB) Receives Consensus Recommendation of "Buy" from AnalystsSpruce Biosciences, Inc. (NASDAQ:SPRB - Get Free Report) has received an average rating of "Buy" from the six brokerages that are presently covering the firm, MarketBeat.com reports. Six equities research analysts have rated the stock with a buy recommendation. The average twelve-month target pricJanuary 30, 2024 | finance.yahoo.comSpruce Biosciences to Present at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceJanuary 25, 2024 | marketbeat.comSpruce Biosciences, Inc. (NASDAQ:SPRB) Short Interest Down 74.4% in JanuarySpruce Biosciences, Inc. (NASDAQ:SPRB - Get Free Report) saw a large decrease in short interest in the month of January. As of January 15th, there was short interest totalling 19,700 shares, a decrease of 74.4% from the December 31st total of 77,000 shares. Based on an average daily trading volume, of 180,400 shares, the short-interest ratio is presently 0.1 days.January 22, 2024 | finance.yahoo.comSpruce Biosciences Completes Enrollment in CAHmelia-204 Study for Adult Classic Congenital Adrenal HyperplasiaJanuary 12, 2024 | marketbeat.comSpruce Biosciences, Inc. (NASDAQ:SPRB) Sees Significant Increase in Short InterestSpruce Biosciences, Inc. (NASDAQ:SPRB - Get Free Report) saw a large increase in short interest in December. As of December 31st, there was short interest totalling 77,000 shares, an increase of 64.5% from the December 15th total of 46,800 shares. Based on an average trading volume of 176,000 shares, the days-to-cover ratio is presently 0.4 days.January 5, 2024 | markets.businessinsider.comBuy Rating Affirmed for Spruce Biosciences Amid Positive Clinical Trials and Market Potential for TildacerfontJanuary 5, 2024 | finance.yahoo.comSpruce Biosciences Reports Baseline Characteristics from CAHmelia-203 and CAHmelia-204 Studies in Adult Classic CAHJanuary 4, 2024 | finance.yahoo.comSpruce Biosciences Provides Clinical Program Updates and Outlook for 2024 Get Spruce Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for SPRB and its competitors with MarketBeat's FREE daily newsletter. Email Address Shocking $16T Elon Musk Crypto Leak (Ad)There’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay attention to above all others: Venture capital firms. You want to follow venture capital money into cryptocurrencies before anyone gets word of what’s happening. Click here for all the details… SPRB Media Mentions By Week SPRB Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SPRB News Sentiment▼0.270.55▲Average Medical News Sentiment SPRB News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SPRB Articles This Week▼161▲SPRB Articles Average Week Get Spruce Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for SPRB and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Fortress Biotech News Today BriaCell Therapeutics News Today NRx Pharmaceuticals News Today Acurx Pharmaceuticals News Today Aprea Therapeutics News Today Apollomics News Today Daré Bioscience News Today ImmunoPrecise Antibodies News Today Viracta Therapeutics News Today Marker Therapeutics News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SPRB) was last updated on 5/17/2024 by MarketBeat.com Staff From Our PartnersInvest in the "Trojan Horse" of Alzheimer's TreatmentBehind the MarketsObama’s Forever Term [exposed]Porter & CompanyThe 1,000X Crypto PlaybookTrue Market InsidersCharles Payne Demystifies OptionsUnstoppable ProsperityBiden FINISHED On June 13th?Paradigm PressWhy Is Gold On a MASSIVE rally? Huge AlertsShocking $16T Elon Musk Crypto LeakCrypto 101 MediaBiden Nomination CANCELED?The Freeport Society Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Spruce Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
